Risk Assessment of Inappropriate Medication Continuation

Abstract

The inappropriate continuation of medications, especially in hospitalized or transitioning patients, is a significant and underrecognized clinical risk. This review systematically explores the factors contributing to the inappropriate persistence of therapies, epidemiological data, underlying mechanisms, risk factors, and the clinical consequences. It further evaluates evidence-based diagnostic and management strategies, recent advances in medication safety, and updated guideline recommendations. The goal is to provide clinicians and healthcare professionals with a comprehensive, practical framework for risk assessment and mitigation of inappropriate medication continuation, ultimately improving patient safety and outcomes.

Introduction

Inappropriate medication continuation refers to the persistence of drug therapies beyond their intended indication, duration, or in the absence of ongoing clinical benefit. This phenomenon is particularly prevalent during care transitions, such as hospital admission or discharge, and in complex patient populations like the elderly or those with polypharmacy. The consequences can be severe, leading to adverse drug events (ADEs), increased healthcare utilization, and diminished quality of life. Understanding the scale, mechanisms, and clinical implications of inappropriate medication continuation is crucial for the implementation of effective risk assessment and intervention strategies.

Epidemiology / Disease Burden

Recent studies estimate that up to 50% of older adults are discharged from hospitals with at least one potentially inappropriate medication (PIM). The prevalence is even higher in long-term care settings and among patients with multiple comorbidities. Data from international pharmacoepidemiological surveys underline that inappropriate continuation often involves medications such as proton pump inhibitors, benzodiazepines, antipsychotics, and anticoagulants. These trends contribute significantly to the burden of ADEs, unnecessary hospital readmissions, and increased healthcare costs. The World Health Organization has identified medication safety, including the cessation of unnecessary drugs, as a global patient safety priority.

Pathophysiology

The pathophysiology underlying inappropriate medication continuation is multifactorial. At the patient level, altered pharmacokinetics and pharmacodynamics in the elderly or those with organ dysfunction can increase susceptibility to adverse effects when medications are unnecessarily continued. Cognitive impairment and fragmented communication between healthcare providers further exacerbate the risk. From a systems perspective, lack of standardized medication reconciliation processes and reliance on incomplete medical records can perpetuate legacy prescribing. These mechanisms underscore the need for vigilance and systematic interventions at every care transition.

Risk Factors

Key risk factors associated with inappropriate continuation include advanced age, polypharmacy (usually defined as five or more concurrent medications), multiple prescribers, poor communication during transitions of care, and absence of regular medication reviews. Specific drug classes are also at higher risk, such as sedative-hypnotics, anticholinergics, and antithrombotics. Patient-related factors, including limited health literacy and cognitive decline, further compound the probability of inappropriate continuation. Institutional factors such as inadequate clinical decision support systems and time constraints in busy clinical environments also play a pivotal role.

Clinical Features

Inappropriate medication continuation may present with non-specific clinical features or as acute adverse drug reactions. Common manifestations include delirium, falls, bleeding, renal impairment, and electrolyte disturbances. Chronic exposure may lead to insidious effects, such as cognitive decline, frailty, and increased morbidity. The clinical impact is often underappreciated, as symptoms may be attributed to underlying disease rather than drug toxicity. Importantly, medication-related harm is frequently preventable through systematic review and de-prescribing where appropriate.

Diagnosis

Diagnosis of inappropriate medication continuation requires a structured medication review, considering each drug's current indication, duration, and risk-benefit profile. Tools such as the STOPP/START criteria and Beers Criteria provide evidence-based guidance for identifying PIMs in older adults. Medication reconciliation at every transition of care is essential to detect unintentional continuation. Involving multidisciplinary teams, including pharmacists, can enhance the accuracy of medication assessments. Laboratory monitoring and clinical evaluation for drug-related adverse effects further inform the diagnostic process.

Treatment & Management

The mainstay of management involves regular, structured medication reviews and timely de-prescribing of unnecessary or harmful medications. Interventions should be multidisciplinary, involving physicians, pharmacists, and nursing staff, with clear documentation of indications and anticipated duration for all therapies. Patient engagement and education are critical, as is shared decision-making, particularly when balancing the risks and benefits of discontinuing chronic therapies. Electronic health record (EHR)-integrated clinical decision support and standardized medication reconciliation protocols can reduce inappropriate continuation and related adverse outcomes.

Recent Advances / Emerging Therapies

Recent advances include the development of sophisticated clinical decision support tools that integrate patient-specific risk factors and updated evidence into prescribing workflows. Artificial intelligence and machine learning algorithms are being piloted to predict patients at high risk for inappropriate continuation and ADEs. Pharmacogenomic profiling offers potential for individualized risk assessment, particularly for drugs with narrow therapeutic indices. Educational interventions, such as academic detailing and prescriber feedback, have demonstrated efficacy in reducing PIM rates. Implementation science approaches are being employed to optimize the uptake of de-prescribing interventions at the health system level.

Guideline Recommendations

Major guidelines, including those from the American Geriatrics Society and the National Institute for Health and Care Excellence (NICE), recommend routine medication review and de-prescribing, particularly in older adults and patients with complex comorbidities. The WHO's Global Patient Safety Challenge on Medication Safety emphasizes medication reconciliation at all transitions of care. Guidelines advocate for the use of validated assessment tools, patient-centered care, and multidisciplinary collaboration. Clear documentation of medication indications and regular reassessment are highlighted as essential components of safe prescribing practices.

Conclusion

The risk assessment of inappropriate medication continuation is a critical component of medication safety and high-quality patient care. Understanding epidemiology, mechanisms, and risk factors enables clinicians to identify vulnerable patients and intervene proactively. Advances in clinical decision support, pharmacogenomics, and structured de-prescribing protocols are transforming practice, but ongoing vigilance is required. Adherence to guideline recommendations and multidisciplinary collaboration are essential for minimizing harm and optimizing therapeutic outcomes. Continued research and education in this domain will further enhance patient safety and the rational use of medications.